EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> G20 Leaders Declare General Commitment To Advance Global Health 01/07/2019 David Branigan Heads of state from the world’s largest economies concluded this year’s G20 Summit in Japan with a general declaration committing to advance global health priorities – but the statement still left much to be desired in terms of concrete goals and targets. In the G20 Osaka Leaders’ Declaration, issued on Saturday at the close of […] Continue reading -> Gavi’s New 5-Year Strategy Prioritises Equity In Immunisation, Sustainable Financing 28/06/2019 David Branigan Gavi, the Vaccine Alliance, just finalised its new strategic plan for 2021-2025, which aims to reach communities missed by previous immunisation efforts, including those most marginalised by poverty, geography and conflict. It also prioritises sustainability of vaccine programmes through co-financing arrangements with countries to build domestic investment in health and reduce reliance on Gavi funding. […] Continue reading -> Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries 24/06/2019 Editorial team [By Reuters] NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it[s] Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one […] Continue reading -> Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> Posts navigation Older postsNewer posts
GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> G20 Leaders Declare General Commitment To Advance Global Health 01/07/2019 David Branigan Heads of state from the world’s largest economies concluded this year’s G20 Summit in Japan with a general declaration committing to advance global health priorities – but the statement still left much to be desired in terms of concrete goals and targets. In the G20 Osaka Leaders’ Declaration, issued on Saturday at the close of […] Continue reading -> Gavi’s New 5-Year Strategy Prioritises Equity In Immunisation, Sustainable Financing 28/06/2019 David Branigan Gavi, the Vaccine Alliance, just finalised its new strategic plan for 2021-2025, which aims to reach communities missed by previous immunisation efforts, including those most marginalised by poverty, geography and conflict. It also prioritises sustainability of vaccine programmes through co-financing arrangements with countries to build domestic investment in health and reduce reliance on Gavi funding. […] Continue reading -> Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries 24/06/2019 Editorial team [By Reuters] NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it[s] Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one […] Continue reading -> Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> Posts navigation Older postsNewer posts
G20 Leaders Declare General Commitment To Advance Global Health 01/07/2019 David Branigan Heads of state from the world’s largest economies concluded this year’s G20 Summit in Japan with a general declaration committing to advance global health priorities – but the statement still left much to be desired in terms of concrete goals and targets. In the G20 Osaka Leaders’ Declaration, issued on Saturday at the close of […] Continue reading -> Gavi’s New 5-Year Strategy Prioritises Equity In Immunisation, Sustainable Financing 28/06/2019 David Branigan Gavi, the Vaccine Alliance, just finalised its new strategic plan for 2021-2025, which aims to reach communities missed by previous immunisation efforts, including those most marginalised by poverty, geography and conflict. It also prioritises sustainability of vaccine programmes through co-financing arrangements with countries to build domestic investment in health and reduce reliance on Gavi funding. […] Continue reading -> Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries 24/06/2019 Editorial team [By Reuters] NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it[s] Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one […] Continue reading -> Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> Posts navigation Older postsNewer posts
Gavi’s New 5-Year Strategy Prioritises Equity In Immunisation, Sustainable Financing 28/06/2019 David Branigan Gavi, the Vaccine Alliance, just finalised its new strategic plan for 2021-2025, which aims to reach communities missed by previous immunisation efforts, including those most marginalised by poverty, geography and conflict. It also prioritises sustainability of vaccine programmes through co-financing arrangements with countries to build domestic investment in health and reduce reliance on Gavi funding. […] Continue reading -> Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries 24/06/2019 Editorial team [By Reuters] NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it[s] Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one […] Continue reading -> Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> Posts navigation Older postsNewer posts
Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries 24/06/2019 Editorial team [By Reuters] NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it[s] Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one […] Continue reading -> Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> Posts navigation Older postsNewer posts
Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> Posts navigation Older postsNewer posts
WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> Posts navigation Older postsNewer posts
Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> Posts navigation Older postsNewer posts
Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> Posts navigation Older postsNewer posts
Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> Posts navigation Older postsNewer posts